Eleven Biotherapeutics (NASDAQ:EBIO) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

Eleven Biotherapeutics (NASDAQ EBIO) opened at $0.95 on Friday. Eleven Biotherapeutics has a 1 year low of $0.62 and a 1 year high of $2.54. The company has a market cap of $30.36, a P/E ratio of -0.90 and a beta of 3.04.

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.37) EPS for the quarter.

A number of hedge funds have recently modified their holdings of the business. Municipal Employees Retirement System of Michigan purchased a new position in Eleven Biotherapeutics in the 3rd quarter valued at approximately $382,000. Virtu KCG Holdings LLC purchased a new position in Eleven Biotherapeutics in the 2nd quarter valued at approximately $175,000. Finally, Vanguard Group Inc. boosted its position in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 30,600 shares during the period. 3.84% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Eleven Biotherapeutics (EBIO) Upgraded to Sell at ValuEngine” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/eleven-biotherapeutics-ebio-upgraded-to-sell-at-valuengine/1838198.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.